Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

LockeT shows sharply lower complication and failure rates than Perclose in a 172-patient study.

What the company is saying

Catheter Precision is highlighting peer-reviewed clinical evidence that its LockeT suture retention device outperforms the market-leading Perclose VCD on key safety metrics. The company emphasizes that LockeT achieved a 1.2% cumulative access-site complication rate versus 9.3% for Perclose, and a 0.0% device failure rate compared to Perclose's 4.7%. Both devices performed similarly for time to hemostasis and same-day discharge rates, which the company frames as LockeT matching the incumbent on efficiency while surpassing it on safety. CEO David Jenkins positions these results as validation of LockeT's clinical value, explicitly linking device failures to increased hospital costs and longer patient stays. The announcement foregrounds regulatory approvals—FDA registration, CE Mark—and current sales in the US, Europe, and South America, but does not mention commercial traction or sales figures. The tone is confident, focusing on clinical superiority and regulatory readiness.

What the data suggests

The study involved 172 patients and was published in The Journal of Interventional Cardiology, lending credibility to the results. LockeT reduced cumulative access-site complications to 1.2%, a significant improvement over Perclose's 9.3%. The device failure rate was 0.0% for LockeT, compared to 4.7% for Perclose. Both devices were equivalent in time to hemostasis and same-day discharge rates, indicating no efficiency trade-off for the improved safety profile. The data is limited to clinical outcomes and regulatory status; there are no disclosures on revenue, sales volume, or adoption rates. The announcement does not provide evidence for downstream economic benefits such as reduced hospital costs or shorter stays, though it suggests these may follow from lower complication and failure rates. The clinical data is robust and peer-reviewed, but the commercial impact remains unquantified.

Analysis

The announcement is factual and proportionate, focusing on the results of a peer-reviewed clinical study comparing the LockeT device to a market leader. All key claims are realised and supported by disclosed numerical data (complication and failure rates, study size, regulatory approvals, and current sales regions). There are no forward-looking projections or exaggerated claims about future financial performance, market share, or commercial adoption. The CEO's statement interprets the data positively but does not overstate beyond what the study supports. No large capital outlay or long-dated benefit is mentioned, and the benefits (clinical outcomes and regulatory status) are already realised. The only minor inflation is in the CEO's use of 'validate,' but this is within normal bounds for clinical result interpretation.

Risk flags

• ●There is no disclosure of commercial adoption, sales figures, or revenue, so the degree to which these clinical results will translate into market share or financial performance is unknown. Without evidence of hospital uptake or purchasing contracts, the impact on earnings is speculative.
• ●The announcement does not address potential competitive responses from Abbott or other VCD manufacturers, which could limit LockeT's market penetration even with superior clinical data. Market incumbency and established relationships may pose barriers.
• ●The clinical study, while peer-reviewed and involving 172 patients, represents a single comparative trial. Broader adoption may require additional studies, real-world data, or endorsements from key opinion leaders to influence purchasing decisions at scale.

Bottom line

This announcement provides strong, peer-reviewed evidence that LockeT outperforms the market-leading Perclose device on complication and failure rates, with 1.2% versus 9.3% complications and 0.0% versus 4.7% failures. LockeT is already FDA-registered, CE Marked, and available in major markets, so regulatory barriers are low. However, the company does not disclose any sales, revenue, or adoption metrics, leaving the commercial impact unproven. Investors should see this as a credible clinical win, but the absence of financial or market uptake data means the investment case remains incomplete. The most important takeaway is that LockeT has established a clear clinical advantage; the next catalyst will be evidence of commercial traction or revenue growth.

Announcement summary

(NYSE:VJET) Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc., announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access. The peer-reviewed study, titled "Vascular closure with a suture retention device versus suture-mediated closure system after large bore venous access for electrophysiologic procedures," included 172 patients and was published in The Journal of Interventional Cardiology (JICE). The study compared the LockeT device to Perclose, a leading internal VCD manufactured and sold by Abbott. The clinical data showed that LockeT reduced cumulative access-site complications to 1.2%, compared to 9.3% with Perclose. The LockeT device achieved a 0.0% failure rate, outperforming the VCD's 4.7% failure rate. Both methods delivered similar results for time to hemostasis and rates of same-day patient discharge. David Jenkins, CEO of Catheter Precision, stated that the findings validate LockeT's efficiency in achieving hemostasis and enabling same-day discharge, while providing the advantages of fewer complications and zero device failures. Jenkins noted that device failures in a clinical setting may directly cause access-site complications, leading to increased costs for hospitals, extended patient stays, and increased monitoring times. LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval, and is now selling in the US, Europe, and South America. Catheter Precision is a U.S.-based medical device company focused on developing technology for electrophysiology procedures. Flyte Aviation, Inc. is a holding company for Fly Flyte and Ponderosa Air, with Fly Flyte operating a fleet of Cirrus Vision Jets and providing private air travel throughout the United States and select international markets.

Disagree with this article?